GNR-067 (ranibizumab biosimilar)
/ Generium
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
September 13, 2023
NAP: Efficacy, Safety, pharmacokinetiсs, Immunogenicity of GNR-067 and Lucentis®
(clinicaltrials.gov)
- P3 | N=408 | Recruiting | Sponsor: AO GENERIUM | Trial primary completion date: Aug 2023 ➔ Aug 2024
Trial primary completion date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration
August 03, 2022
NAP: Efficacy, Safety, pharmacokinetiсs, Immunogenicity of GNR-067 and Lucentis®
(clinicaltrials.gov)
- P3 | N=408 | Recruiting | Sponsor: AO GENERIUM | Not yet recruiting ➔ Recruiting
Enrollment open • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration
1 to 2
Of
2
Go to page
1